Selatox Bio Pharma confirms the successful completion of Phase III global clinical trials for its lead aesthetic indication, representing a major step toward expanded regulatory submissions in priority markets. The program enrolled participants across multiple regions, with investigator sites adhering to harmonised protocols, centralized monitoring, and predefined statistical analysis plans reviewed by external advisors.
Primary and secondary endpoints addressed efficacy, tolerability, and practitioner-reported outcomes, including standardized photography review, patient-reported satisfaction instruments, and safety surveillance for adverse events of special interest. Independent committees conducted interim reviews in accordance with charter obligations, and no trial-stopping safety signals were observed during the final analysis window.
Data management teams have locked clinical databases and initiated preparation of integrated summaries for health authorities, incorporating manufacturing comparability references, pharmacovigilance histories, and proposed labeling claims supported by evidence tables. Regulatory affairs staff are coordinating sequencing of filings to balance resource capacity with market readiness criteria established by regional partners.
Selatox thanked investigators, coordinators, and participants for disciplined execution throughout recruitment and follow-up periods that spanned seasonal operational challenges. The company noted that medical affairs will release educational materials aligned with approved indications once regulatory decisions are obtained, ensuring responsible communication with healthcare professionals.
Until formal approvals are granted, Selatox reminds stakeholders that investigational product must not be promoted for unapproved uses. Updates on submission milestones will be communicated through official newsroom channels and direct partner notifications as appropriate.
